Johnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on Tuesday
Johnson & Johnson (NYSE:JNJ) is set to issue its Q316 quarterly earnings data on Tuesday, October 18th. Analysts expect the company to announce earnings of $1.66 per share and revenue of $17.71 billion for the quarter.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. On average, analysts expect Johnson & Johnson to post $6.69 EPS for the current fiscal year and $7.11 EPS for the next fiscal year.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 118.26 on Friday. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The stock has a market capitalization of $323.54 billion, a price-to-earnings ratio of 22.04 and a beta of 0.62. The stock’s 50 day moving average is $118.75 and its 200-day moving average is $117.30.
A number of brokerages have recently weighed in on JNJ. Credit Suisse Group AG restated a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a report on Monday, September 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. BMO Capital Markets reiterated an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research note on Friday, August 5th. Finally, Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.13 price target on the stock in a research note on Tuesday, September 27th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $120.19.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the company. Cambridge Trust Co. boosted its position in shares of Johnson & Johnson by 3.1% in the second quarter. Cambridge Trust Co. now owns 306,988 shares of the company’s stock worth $37,238,000 after buying an additional 9,161 shares during the last quarter. Hyman Charles D raised its position in Johnson & Johnson by 1.1% in the second quarter. Hyman Charles D now owns 262,363 shares of the company’s stock worth $31,825,000 after buying an additional 2,748 shares in the last quarter. Argent Trust Co raised its position in Johnson & Johnson by 0.6% in the second quarter. Argent Trust Co now owns 39,093 shares of the company’s stock worth $4,743,000 after buying an additional 238 shares in the last quarter. Dana Investment Advisors Inc. raised its position in Johnson & Johnson by 17.2% in the second quarter. Dana Investment Advisors Inc. now owns 338,166 shares of the company’s stock worth $41,020,000 after buying an additional 49,573 shares in the last quarter. Finally, Reilly Herbert Faulkner III purchased a new position in Johnson & Johnson during the second quarter worth $4,389,000. Institutional investors own 65.32% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.